KRAS and colonic neoplasm: In addition to its direct inhibitory effect on KRAS-mutant cancer cells, sotorasib was found to promote antitumor immunity in a syngeneic CT-26 KRAS G12C colon cancer model by creating a pro-inflammatory tumor microenvironment [48].